The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
The test detects and differentiates respiratory syncytial virus and human metapneumovirus on the firm's Solana rapid molecular platform.
The assay runs on the Panther Fusion system, which combines transcription-mediated amplification, real-time TMA, and real-time PCR with full sample-to-result automation.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.